REPRIEVE: Pitavastatin to Prevent Cardiovascular Disease in HIV

REPRIEVE: Pitavastatin to Prevent Cardiovascular Disease in HIV

HIV patients are known to have up to a two-fold increase in heart-related events, compared with the general population. Could treatment with statins reduce this risk?

Dr. Steven Fine, an infectious disease specialist affiliated with the University of Rochester, reviews the recently published results of the REPRIEVE trial. The big picture is a 35% reduction in heart-related events. Dr. Fine digs into the details and statistics of the trial, and the encouraging results of statin treatment, even in those deemed to be at lower risk. Related Content:

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(63)

Introducing Point-of-Care Testing for Hepatitis C

Introducing Point-of-Care Testing for Hepatitis C

New York State’s Hepatitis C Dashboard shows that in 2023, 4,783 people were newly diagnosed with HCV in the state, an 8% decrease from 2022. Incidence also decreased, with the rate of new HCV infecti...

14 Maj 21min

Cannabis and Pregnancy

Cannabis and Pregnancy

Based on data from 2023-24, roughly 23% of New Yorkers aged 21 or older reported cannabis use in the past 12 months. Although men generally have a higher prevalence of use than women, recent studies s...

20 Apr 22min

CROI 2026 – Live from Denver: What You Need to Know

CROI 2026 – Live from Denver: What You Need to Know

Conference on Retroviruses and Opportunistic Infections (CROI) 2026 took place from February 22 to 25 in Denver, Colorado. CROI is an annual scientific meeting devoted to the understanding, prevention...

7 Apr 15min

Misconceptions about Contraception

Misconceptions about Contraception

Host Dr. Erica Bostick from the University of Rochester Medical Center Division of Adolescent Medicine chats with Dr. Stacy Sun, a double board-certified physician in obstetrics and gynecology and com...

12 Mars 33min

What “The 72-Hour Rule” Update Means for New York State

What “The 72-Hour Rule” Update Means for New York State

Effective February 19, 2026, New York State law permits clinicians to dispense up to 72 hours (equivalent to a 3-day supply) of controlled substances, such as methadone and buprenorphine, for the mana...

17 Feb 19min

Two New Treatments for Gonorrhea; one is available now!

Two New Treatments for Gonorrhea; one is available now!

In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights th...

12 Jan 15min

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV.  Subcutaneous lenacapavir is administer...

20 Nov 202528min

Keeping an Eye on STIs – Have You Heard of TMVII?

Keeping an Eye on STIs – Have You Heard of TMVII?

This month, host Dr. Marguerite Urban chats with Dr. Jason Zucker, an adult and pediatric infectious diseases physician at Columbia University and the assistant medical director of the New York City H...

13 Nov 202518min

Populärt inom Utbildning

historiepodden-se
det-skaver
rss-bara-en-till-om-missbruk-medberoende-2
allt-du-velat-veta
nu-blir-det-historia
harrisons-dramatiska-historia
sektledare
johannes-hansen-podcast
not-fanny-anymore
roda-vita-rosen
rss-viktmedicinpodden
i-vantan-pa-katastrofen
rss-dr-bjorklund
sa-in-i-sjalen
rss-max-tant-med-max-villman
rss-real-talk-with-jesper-stahl
rss-basta-livet
rss-foraldramotet-bring-lagercrantz
rss-relationsrevolutionen
rss-sjalsligt-avkladd